Monogenic diabetes – Diagnostics – Overview of Information and Clinical Research

Monogenic diabetes is a rare form of diabetes caused by a change in a single gene, making it fundamentally different from the more common type 1 and type 2 diabetes that most people know about. While it accounts for only about 1% to 5% of all diabetes cases, correct diagnosis through genetic testing can dramatically change treatment options, sometimes allowing people to switch from insulin injections to oral medications, or in some cases, requiring no treatment at all.

Introduction: Who Should Seek Diagnostic Testing for Monogenic Diabetes

Monogenic diabetes is often mistaken for the more common types of diabetes, which means many people may be receiving treatments that are not the best fit for their condition. Because this form of diabetes is rare and not widely recognized, understanding when to seek specialized diagnostic testing is crucial for getting the right care.^[1]

If you or your child have been diagnosed with diabetes at a young age—typically before 30 years old, and especially before 25—but do not quite fit the usual pattern of either type 1 or type 2 diabetes, it may be worth discussing monogenic diabetes testing with your healthcare provider. This is particularly important if diabetes runs strongly in your family, appearing in multiple generations, which suggests a pattern of inheritance rather than chance.^[2]

You should consider seeking diagnostic evaluation if you or your child are not overweight or obese, which is more typical of type 2 diabetes, and if blood tests show that your body is still producing some insulin several years after diagnosis. This is different from type 1 diabetes, where the body typically stops making insulin entirely. If tests for the antibodies that attack insulin-producing cells in type 1 diabetes come back negative, this is another important clue that monogenic diabetes might be the correct diagnosis.^[10]

Babies diagnosed with diabetes in the first six months of life almost always have a form of monogenic diabetes called neonatal diabetes mellitus, or NDM. In these cases, genetic testing is particularly important because knowing the specific gene involved can guide treatment decisions right from the start.^[1]

⚠️ Important

Many people with monogenic diabetes—up to 80% according to some estimates—are misdiagnosed as having type 1 or type 2 diabetes. This misdiagnosis can lead to unnecessary treatments, such as insulin injections when oral medications might work better, or intensive treatments when none might be needed at all. Getting the correct diagnosis through genetic testing opens the door to personalized, more effective care.

Classic Diagnostic Methods for Identifying Monogenic Diabetes

Diagnosing monogenic diabetes involves a combination of clinical observation, standard diabetes tests, and specialized genetic testing. The process begins with your healthcare provider carefully reviewing your medical history, family history, and the circumstances surrounding your diabetes diagnosis.^[10]

Initial Clinical Assessment

The first step in identifying possible monogenic diabetes is recognizing patterns that do not fit typical type 1 or type 2 diabetes. Your healthcare provider will ask detailed questions about when your diabetes was diagnosed, your age at diagnosis, and whether other family members across multiple generations have diabetes. They will also examine your weight and look for signs of obesity or other metabolic conditions that are more common with type 2 diabetes.^[16]

A strong family history of diabetes is one of the most important clues. Monogenic diabetes is usually inherited in what doctors call an autosomal dominant pattern, which means that if one parent has the genetic change causing the condition, each of their children has a 50% chance of inheriting it. When doctors see diabetes affecting parents, children, and grandchildren, this hereditary pattern suggests monogenic diabetes rather than type 1 or type 2.^[7]

Standard Laboratory Tests

Before proceeding to genetic testing, healthcare providers use several blood tests to help distinguish monogenic diabetes from other types. One key test measures C-peptide, which is a substance that shows how much insulin your body is producing. In people with monogenic diabetes, C-peptide levels are typically still detectable three to five years after diagnosis, indicating that the pancreatic beta cells—the cells that make insulin—are still functioning. This is different from type 1 diabetes, where these cells are destroyed and C-peptide levels drop to very low or undetectable levels.^[10]

Another important set of tests looks for islet autoantibodies, which are proteins the immune system makes when it attacks the insulin-producing cells. The main antibodies doctors test for include GAD (glutamic acid decarboxylase), IA2 (insulinoma-associated-2), and ZnT8 (zinc transporter 8). In monogenic diabetes, these antibody tests typically come back negative because the condition is caused by a genetic change rather than an immune system attack on the pancreas.^[7]

Blood sugar measurements also provide important clues. Some forms of monogenic diabetes, particularly one type called GCK-MODY, cause mild but stable elevations in fasting blood sugar, typically between 5.5 and 8 millimoles per liter. People with this form often have HbA1c levels—a measure of average blood sugar over several months—ranging from 5.7% to 7.5%. These levels are higher than normal but relatively stable throughout life, without the progressive worsening seen in other diabetes types.^[7]

Genetic Testing

Genetic testing is the only way to definitively diagnose monogenic diabetes and identify which specific gene is involved. This testing analyzes your DNA, which can be obtained from a blood sample or sometimes from saliva. The laboratory examines the genes known to cause monogenic diabetes, looking for changes or mutations that affect how your body makes or uses insulin.^[9]

More than 20 different genes have been found to cause various forms of monogenic diabetes, though most cases are caused by changes in just a few genes. The two most common are the GCK gene and the HNF1A gene. Modern genetic testing typically uses a technique called massively parallel sequencing, which allows laboratories to examine all the known monogenic diabetes genes at once, rather than testing them one at a time. This approach is more efficient and increases the chances of finding the genetic cause.^[7]

The genetic test successfully identifies a specific genetic cause in about 80% of babies with neonatal diabetes diagnosed under six months of age. For young people diagnosed later in childhood or early adulthood with features suggesting monogenic diabetes, the test finds a genetic cause in roughly 25% to 70% of cases, depending on how closely they fit the classic pattern for monogenic diabetes.^[7]

Results from genetic testing typically take several weeks to return. When a genetic change is identified, the report will specify which gene is affected and, when possible, what this means for treatment and long-term outlook. In some cases, testing may not find a known genetic cause, even when monogenic diabetes is strongly suspected. This could mean the person has a change in a gene that has not yet been discovered, or that they have a different form of diabetes.^[10]

Additional Testing to Distinguish Diabetes Types

In young people diagnosed with diabetes, healthcare providers may use additional criteria to help decide who should undergo genetic testing. For someone diagnosed with diabetes before 30 years of age who does not have obesity, preserved insulin production (shown by C-peptide), negative antibody tests, and a strong family history, the likelihood of monogenic diabetes is high enough to justify genetic testing.^[16]

For women who show mild elevations in blood sugar during pregnancy, particularly if they have the pattern of stable, mildly elevated fasting blood sugar typical of GCK-MODY, rapid genetic testing may be offered during pregnancy. This is because knowing whether the mother, the baby, or both have the genetic change can help guide decisions about treatment during pregnancy.^[7]

Challenges in Diagnosis

One of the biggest challenges in diagnosing monogenic diabetes is that many healthcare providers are not familiar with these rare forms of diabetes. Because type 1 and type 2 diabetes are so much more common, doctors often assume a young person with diabetes has type 1, or that an adult with diabetes has type 2, without considering the possibility of monogenic diabetes.^[5]

Another challenge is that the symptoms of monogenic diabetes can be very similar to those of other diabetes types. These symptoms include increased thirst, frequent urination, unexplained weight loss, blurred vision, and fatigue. Because these symptoms do not point specifically to monogenic diabetes, healthcare providers must rely on additional factors like family history, age at diagnosis, body weight, and laboratory test results to identify who should be tested.^[1]

⚠️ Important

Genetic testing for monogenic diabetes is increasingly accessible and may be covered by insurance or healthcare systems in some countries, particularly when specific clinical criteria are met. If you suspect you or a family member might have monogenic diabetes, ask your healthcare provider about referral to a specialist in endocrinology or diabetes who has experience with monogenic forms of diabetes.

Diagnostics for Clinical Trial Qualification

When researchers conduct clinical trials to test new treatments for monogenic diabetes, they use specific diagnostic tests and criteria to make sure participants truly have the condition being studied. These qualification criteria are typically more rigorous than those used for routine clinical diagnosis, helping to ensure that the study results are reliable and applicable to people with confirmed monogenic diabetes.^[5]

Genetic confirmation is the cornerstone of qualification for most monogenic diabetes clinical trials. Trial organizers require documented evidence from an accredited genetic testing laboratory showing that the participant has a pathogenic variant—a genetic change known to cause disease—in the specific gene being studied. This documentation must typically include details about which gene is affected and precisely what the genetic change is.^[10]

For trials studying particular subtypes of monogenic diabetes, such as those affecting the GCK, HNF1A, or HNF4A genes, researchers will only enroll participants with confirmed mutations in that specific gene. This is because different genetic causes of monogenic diabetes may respond differently to treatments, and mixing different subtypes in a single trial could make it impossible to determine whether a treatment works.^[2]

Beyond genetic confirmation, clinical trials often require specific measurements of diabetes control and insulin production. Researchers commonly measure HbA1c levels to establish how well controlled a participant’s blood sugar has been over the previous two to three months. Trials may set both minimum and maximum HbA1c levels—for example, requiring levels between 6.5% and 10%—to ensure participants have active diabetes but not extremely high blood sugar that might pose safety risks during the study.^[14]

C-peptide testing is frequently required to confirm that participants are still producing some of their own insulin, which is characteristic of many forms of monogenic diabetes. The level of C-peptide can help researchers understand how much natural insulin production remains and whether a treatment aimed at stimulating insulin release might be effective. Some trials require testing C-peptide both when fasting and after consuming glucose or a meal to see how the pancreas responds to rising blood sugar.^[10]

For trials enrolling people with neonatal diabetes, additional documentation about the age at diagnosis and initial presentation is typically required. Because some babies initially diagnosed with neonatal diabetes later turn out to have other rare conditions, trial organizers need to verify that the diagnosis and genetic findings are consistent with the specific form of neonatal diabetes under study.^[1]

Clinical trials may also require tests to confirm that participants do not have type 1 diabetes. This usually involves testing for the islet autoantibodies mentioned earlier—GAD, IA2, and ZnT8 antibodies. Participants must test negative for these antibodies to confirm that their diabetes is due to a genetic cause rather than autoimmune destruction of insulin-producing cells.^[7]

Some trials studying treatments for specific subtypes may require additional specialized testing. For example, studies of treatments for HNF1A-MODY might test for glycosuria—the presence of glucose in urine even when blood sugar is not extremely elevated—which is a characteristic feature of this subtype. Other trials might require kidney function tests, particularly for subtypes like HNF1B-MODY that can affect the kidneys as well as blood sugar control.^[3]

Family history documentation is sometimes requested in clinical trials, not only to support the diagnosis but also to understand patterns of disease severity and progression within families. Some trials may even test family members to confirm the inheritance pattern and better understand the genetic basis of the condition.^[10]

Age requirements vary by trial depending on what is being studied. Some trials focus specifically on children or adolescents with newly diagnosed monogenic diabetes, while others enroll adults who have had the condition for many years. Age restrictions help ensure the safety of participants and allow researchers to study treatments at specific life stages when they might be most beneficial.^[14]

Importantly, many clinical trials exclude people who have diabetes-related complications such as severe kidney disease, significant heart disease, or advanced eye damage. This is both for safety reasons and to allow clearer assessment of whether the treatment being studied affects blood sugar control, without the confounding effects of complications that might influence results or put participants at risk.^[8]

Prognosis and Survival Rate

Prognosis

The outlook for people with monogenic diabetes varies significantly depending on which specific genetic change causes their condition. Some forms have an excellent prognosis with little to no impact on health or lifespan, while others require careful management to prevent complications similar to those seen in more common diabetes types.^[1]

People with GCK-MODY typically have the best prognosis among all diabetes types. This form causes mild, stable elevations in blood sugar throughout life, but these levels are usually not high enough to cause the organ damage—affecting eyes, kidneys, nerves, and heart—commonly seen in other forms of diabetes. Most people with GCK-MODY do not require treatment and can expect a normal lifespan without diabetes-related complications.^[7]

In contrast, people with HNF1A-MODY or HNF4A-MODY have blood sugar levels that tend to progressively increase over time. Without proper treatment, they face similar risks of complications as people with type 1 or type 2 diabetes, including damage to the eyes (diabetic retinopathy), kidneys (diabetic nephropathy), nerves (diabetic neuropathy), and blood vessels that supply the heart and other organs. However, when these forms are correctly diagnosed and treated appropriately—often with oral medications called sulfonylureas rather than insulin—blood sugar can usually be well controlled, and the risk of complications significantly reduced.^[14]

Neonatal diabetes that develops in the first six months of life can be either permanent or temporary. Some babies experience what is called transient neonatal diabetes, where diabetes appears in early infancy but then goes away after a few months. However, it may return later in childhood or early adulthood. The long-term prognosis depends on the specific genetic cause and whether the diabetes is permanent or returns after remission.^[1]

Some genetic changes that cause monogenic diabetes also affect other organs beyond the pancreas. For example, HNF1B-MODY can cause kidney problems, including kidney cysts or abnormal kidney development, which may require additional monitoring and treatment. The prognosis in these cases depends not only on managing blood sugar but also on addressing these additional health concerns.^[3]

One of the most important factors affecting prognosis is whether the correct diagnosis is made. When monogenic diabetes is properly identified through genetic testing, treatment can be tailored to the specific subtype, which often leads to better blood sugar control with simpler treatment regimens. People who remain misdiagnosed may receive unnecessary insulin injections or other treatments that are not optimal for their condition, potentially leading to poorer outcomes.^[8]

Pregnancy outcomes vary by subtype. Women with HNF4A-MODY may have larger-than-average babies (macrosomia), and their newborns may experience low blood sugar in the first hours or days after birth. Women with GCK-MODY typically have good pregnancy outcomes if the baby inherits the same genetic change, but may need treatment during pregnancy if the baby does not inherit the mutation. Knowing the genetic cause allows for appropriate planning and monitoring during pregnancy.^[16]

Survival Rate

Specific survival statistics for monogenic diabetes as a whole are not widely reported in the available medical literature, largely because this group of conditions is quite diverse, with outcomes varying dramatically by subtype. However, the general outlook for survival is favorable when the condition is correctly diagnosed and appropriately managed.^[8]

For people with GCK-MODY, life expectancy is expected to be similar to that of people without diabetes, since this mild form rarely causes significant health complications. These individuals typically do not experience the shortened lifespan sometimes associated with poorly controlled type 1 or type 2 diabetes.^[7]

For other forms of monogenic diabetes that cause higher blood sugar levels and require treatment, survival and life expectancy are closely tied to how well blood sugar is controlled over time and whether diabetes-related complications develop. When blood sugar is well managed through appropriate treatment—which might include oral medications, insulin, or in some cases just dietary modifications—people with monogenic diabetes can expect a normal or near-normal lifespan.^[14]

The risk of life-threatening complications, such as heart attacks, strokes, and kidney failure, increases when blood sugar remains poorly controlled over many years, similar to what is seen in type 1 and type 2 diabetes. However, because many forms of monogenic diabetes respond well to treatment, and because correct diagnosis often leads to simpler, more effective treatment strategies, the outlook is generally good when people receive appropriate care.^[1]

#1 Clinical Trials Search in Europe